Pre-fusion RSV f protein and use thereof

By introducing amino acid mutations and heteropeptide linkages into the RSV F protein, the pre-fusion conformation was stabilized, solving the problems of low neutralizing antibody activity and Th2-biased immune response in RSV vaccines, and achieving efficient immune response and stable expression.

WO2024235285A1PCT designated stage expired Publication Date: 2024-11-21BEIJING WESTAR BIOSCIENCES CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/093642
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2024-05-16
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Due to low neutralizing antibody activity and severe lung inflammation caused by Th2-biased immune responses, there are currently no effective preventive vaccines available for RSV. Furthermore, RSV F protein tends to prematurely refold into its fusion conformation in solution, resulting in poor stability.

Method used

By introducing amino acid mutations into the RSV F protein, including cavity filling, introduction of disulfide bonds, chemical bonds, and polypeptide backbone rotation, the pre-fusion conformation is stabilized. The F1 and F2 peptides are then linked by heteropeptide linkers to form a highly expressed and stable pre-fusion conformation RSV F protein.

Benefits of technology

It improves the stability and immunogenicity of RSV F protein, induces a more efficient neutralizing antibody response, reduces the risk of severe lung inflammation, and provides a more effective vaccine candidate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024093642_21112024_PF_FP_ABST
    Figure CN2024093642_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed in the present invention are a pre-fusion RSV F protein and a use thereof. The pre-fusion RSV F protein comprises one or more amino acid mutations to stabilize an RSV F protein in a pre-fusion conformation. Also disclosed in the present invention are a nucleic acid molecule encoding the protein, a vector, a host cell, and an immune composition comprising the protein.
Need to check novelty before this filing date? Find Prior Art

Description

Prefusion RSV F protein and its application Technical Field

[0001] The present invention belongs to the field of biomedicine and relates to a pre-fusion RSV F protein and an application thereof. Background Art

[0002] Human respiratory syncytial virus (RSV) is a nonsegmented, single-stranded, negative-sense, enveloped RNA virus belonging to the Pneumoviridae family. RSV is a major viral pathogen causing respiratory illness in infants, young children, and the elderly, causing severe lower respiratory tract infections in over 30 million children under the age of five and the death of over 60,000 children annually. Although RSV has been discovered for over 60 years, there remains no effective vaccine to prevent it. In the 1960s, formalin-inactivated RSV (FI-RSV) vaccines adjuvanted with aluminum were first used in infant RSV vaccine research. Unfortunately, this vaccine resulted in severe enhanced respiratory disease (ERD) and high hospitalization rates in vaccinated infants, with two children dying from bronchiolar mononuclear cell infiltration and eosinophilia. FI-RSV causes ERD for two reasons: low neutralizing antibody activity, which is ineffective in neutralizing the virus; and a vaccine-induced Th2-biased immune response, which can lead to severe lung inflammation after challenge. The low neutralizing antibody activity is mainly due to the absence of the prefusion F epitope on the surface of FI-RSV, while a Th2-biased immune response is one of the characteristics of formalin-inactivated virus vaccines. Therefore, a safe and effective RSV vaccine candidate should have both good neutralizing activity and induce a Th1-biased immune response.

[0003] At present, there is still no effective preventive vaccine going on the market. RSV F protein is the most important immunogen, which can induce the body to produce protective neutralizing antibodies. There are two conformations before and after the F protein plays the membrane fusion function, namely the pre-fusion conformation (preF) and the post-fusion conformation (postF), wherein the preF protein can induce more efficient neutralizing antibodies. However, due to its instability, the pre-fusion conformation has the tendency to refold into the post-fusion conformation prematurely in the solution and on the virion surface. The RSV F protein with high expression level and keeping stable pre-fusion conformation will become a promising candidate for the vaccine against RSV.

[0004] Summary of the Invention

[0005] In order to develop RSV F protein with high expression level and stable prefusion conformation, the present invention provides the following technical solutions:

[0006] The first aspect of the present invention provides a mutant RSV F protein comprising at least one amino acid mutation, wherein the amino acid mutation stabilizes the recombinant RSV F protein in a prefusion conformation, wherein the RSV F protein binds to the recognition antigen site. and / or antibody binding to V.

[0007] In some embodiments, the amino acid mutations of the RSV F protein include one or more of: cavity-filling amino acid mutations, disulfide-bond-introducing amino acid mutations, chemical-bond-introducing amino acid mutations, and polypeptide backbone-inducing amino acid mutations.

[0008] In some embodiments, the amino acid mutations include mutating amino acids in close proximity to the α-helix and β-sheet to prevent refolding into the post-fusion conformation.

[0009] In some embodiments, the RSV F protein comprises a mutation at amino acid residue 55, 186-193, 210-217, 254, 255-264, 323, 394, 461, 475, or 491, or at an amino acid corresponding to residue 55, 186-193, 210-217, 254, 255-264, 323, 394, 461, 475, or 491 as determined by alignment with SEQ ID NO. 1, wherein amino acids 255-264 and 186-193 are located near the alpha helix and beta sheet.

[0010] In some embodiments, the RSV F protein comprises a mutation at amino acid residue 55, 188, 190, 210-214, 217, 254, 260, 263, 323, 394, 461, 475, or 491.

[0011] In some embodiments, the RSV F protein comprises a cavity-filling amino acid mutation at position 55, preferably, the cavity-filling amino acid mutation comprises a substitution of F, L, W, V, Y, H, or M. In a preferred embodiment, the cavity-filling amino acid mutation at position 55 is S55V.

[0012] In some embodiments, the RSV F protein comprises amino acid mutations that introduce disulfide bonds at positions 188, 190, 260, 263, 394, 491, 323, and 475. In preferred embodiments, the amino acid mutations that introduce disulfide bonds at positions 188, 190, 260, 263, 394, 491, 323, and 475 are substituted with cysteine. In preferred embodiments, the amino acid mutations that introduce disulfide bonds are selected from one or more of (a)-(d):

[0013] (a) 188C and 263C substitutions;

[0014] (b) 190C and 260C substitution;

[0015] (c) 394C and 491C substitutions; and

[0016] (d) 323C and 475C substitutions.

[0017] In a specific embodiment, the 188C and 263C substitutions are L188C and D263C substitutions;

[0018] The 190C and 260C substitutions are S190C and L260C substitutions;

[0019] The 394C and 491C substitutions are K394C and S491C substitutions;

[0020] The 323C and 475C substitutions are T323C and I475C substitutions.

[0021] In some embodiments, the RSV F protein comprises an amino acid mutation that introduces a chemical bond at position 254. In a preferred embodiment, the amino acid mutation that introduces a chemical bond at position 254 is N254R.

[0022] In some embodiments, the RSV F protein includes amino acid mutations at positions 210-214, 217, and 461 that introduce a rotation-inducing polypeptide backbone. In one embodiment, the amino acid mutations introduced to induce polypeptide backbone rotation include proline substitutions. In a specific embodiment of the invention, the amino acid mutations at positions 210-214, 217, and 461 that introduce a rotation-inducing polypeptide backbone are Q210P, C212P, S213P, I214P, I217P, or K461P.

[0023] In some embodiments, the RSV F protein includes the amino acid mutation of cavity filling, the amino acid mutation introducing a chemical bond and at least one amino acid mutation introducing a disulfide bond. In some embodiments, the RSV F protein includes following mutations: S55V, N254R, S190C and L260C.

[0024] In other embodiments, the RSV F protein includes a mutation at position 461 and at least one amino acid mutation that introduces a disulfide bond. In a preferred embodiment, the RSV F protein includes the following mutations:

[0025] K461P, K394C, and S491C; or

[0026] K461P, T323C and I475C.

[0027] In some embodiments, the RSV F protein comprises any of the aforementioned RSV F mutant proteins other than position 215 and a mutation at position 215. In a preferred embodiment, the mutation at position 215 is S215P.

[0028] In some embodiments, the RSV F protein comprises a Fi polypeptide and an F2 polypeptide, and optionally does not comprise a pep27 polypeptide or a portion thereof. In some embodiments that do not comprise a pep27 polypeptide or a portion thereof, the C-terminal residue of the F2 polypeptide and the N-terminal residue of the Fi polypeptide comprise RSV F positions 97 and 137, 97 and 145, 97 and 150, 102 and 144, 102 and 145, 102 and 146, 102 and 147, 103 and 144, 103 and 145, 103 and 146, 103 and 147, 104 and 144, 104 and 145, 104 and 146, 104 and 147, 105 and 144, 105 and 145, 105 and 146, 105 and 147, or 105 and 150, respectively.

[0029] In an embodiment of the present invention, the F2 and F1 polypeptides are linked via a heterologous peptide linker or directly linked. The linker includes, but is not limited to, G, S, GG, GS, SG, PS, GP, GGG, or GSG. In one embodiment, position 103 of the F2 polypeptide is linked to position 145 of the F1 polypeptide via a GS linker. In one embodiment, position 103 of the F2 polypeptide is directly linked to position 145 of the F1 polypeptide. In one embodiment, position 103 of the F2 polypeptide is linked to position 145 of the F1 polypeptide via a PS linker. In another embodiment, position 103 of the F2 polypeptide is linked to position 147 of the F1 polypeptide via a GP linker.

[0030] In some embodiments of the invention, the RSV F protein comprises the following amino acid mutations: S215P and a deletion of the pep27 polypeptide or a portion thereof. In a preferred embodiment, the F2 and F1 polypeptides of the RSV F protein are connected by a heterologous peptide linker. In a specific embodiment, position 103 of the F2 polypeptide is connected to position 145 of the F1 polypeptide via a GS linker.

[0031] In some embodiments of the present invention, the RSV F protein comprises the following amino acid mutations: S55V, S190C, L260C, N254R, and S215P. In a preferred embodiment, the RSV F protein does not comprise the pep27 polypeptide or a portion thereof. In a preferred embodiment, the F2 and F1 polypeptides of the RSV F protein are connected by a heterologous peptide linker. The linker includes, but is not limited to, the aforementioned linker, and the connection position includes, but is not limited to, the position of the C-terminal residue of the F2 polypeptide and the N-terminal residue of the F1 polypeptide. In a specific embodiment, position 103 of the F2 polypeptide is connected to position 145 of the F1 polypeptide via a GS linker. In another specific embodiment, position 103 of the F2 polypeptide is connected to position 145 of the F1 polypeptide via a PS linker. In another specific embodiment, position 103 of the F2 polypeptide is connected to position 147 of the F1 polypeptide via a GP linker.

[0032] In some embodiments of the invention, the RSV F protein comprises the following amino acid mutations: S55V, S190C, L260C and N254R, and one or more of Q210P, S211P, C212P, S213P, I214P, S215P or I217P. Optionally, the RSV F protein does not comprise a pep27 polypeptide or a portion thereof. In a preferred embodiment, the F2 and F1 polypeptides of the RSV F protein are connected by a heterologous peptide connexon. The connexon includes, but is not limited to, the aforementioned connexon, and the connection position includes, but is not limited to, the position of the C-terminal residue of the aforementioned F2 polypeptide and the N-terminal residue of the F1 polypeptide.

[0033] In a specific embodiment, the RSV F protein comprises the following amino acid mutations: S55V, S190C, L260C, N254R, and S215P, and position 103 of the F2 polypeptide is linked to position 145 of the F1 polypeptide via a GS linker. In a specific embodiment, the RSV F protein comprises the following amino acid mutations: S55V, S190C, L260C, N254R, and S215P, and position 103 of the F2 polypeptide is linked to position 145 of the F1 polypeptide via a PS linker.

[0034] In a specific embodiment, the RSV F protein comprises the following amino acid mutations: S55V, S190C, L260C, N254R, and S215P, and position 103 of the F2 polypeptide is linked to position 147 of the F1 polypeptide via a GP linker.

[0035] In some embodiments of the invention, the RSV F protein comprises the following amino acid mutations: K461P, K394C, S491C, and S215P. Optionally, the RSV F protein does not comprise a pep27 polypeptide or a portion thereof. In a preferred embodiment, the F2 and F1 polypeptides of the RSV F protein are connected by a heterologous peptide linker. The linker includes, but is not limited to, the aforementioned linker, and the connection position includes, but is not limited to, the position of the C-terminal residue of the F2 polypeptide and the N-terminal residue of the F1 polypeptide.

[0036] In a specific embodiment, the RSV F protein comprises the following amino acid mutations: K461P, K394C, S491C, and S215P, and position 103 of the F2 polypeptide is linked to position 145 of the F1 polypeptide via a GS linker.

[0037] In some embodiments of the invention, the RSV F protein comprises the following amino acid mutations: K461P, T323C, I475C, and S215P. Optionally, the RSV F protein does not comprise the pep27 polypeptide or a portion thereof. In a preferred embodiment, the F2 and F1 polypeptides of the RSV F protein are connected by a heterologous peptide linker. The linker includes, but is not limited to, the aforementioned linker, and the connection position includes, but is not limited to, the position of the C-terminal residue of the F2 polypeptide and the N-terminal residue of the F1 polypeptide.

[0038] In a specific embodiment, the RSV F protein comprises the following amino acid mutations: K461P, T323C, I475C, and S215P, and position 103 of the F2 polypeptide is linked to position 145 of the F1 polypeptide via a GS linker.

[0039] In a specific embodiment, the RSV F protein comprises the following amino acid mutations: K461P, T323C, I475C, and S215P, and position 103 of the F2 polypeptide is linked to position 147 of the F1 polypeptide via a GP linker.

[0040] In some embodiments, the RSV F protein is a full-length RSV F protein.

[0041] In some embodiments, the RSV F protein is a soluble RSV F protein.

[0042] In some embodiments, aforementioned any RSV F mutans also includes one or more labels, which can be used for detecting and / or purifying RSV F protein. In one embodiment, described RSV F protein comprises one or more labels for detecting RSV F molecule. In another embodiment, RSV F protein comprises one or more labels for purifying RSV F molecule. Wherein, described label includes but is not limited to Strep tag, Strep II label, FLAG label, glutathione S-transferase (GST) label, green fluorescent protein (GFP) label, hemagglutinin A (HA) label, histidine (His) label, luciferase tag, maltose binding protein (MBP) label, c-Myc label, protein A label or protein G label. In a preferred embodiment, described label is the label that can be cut through proteolysis.

[0043] In some embodiments, any of the aforementioned RSV F mutant proteins can be proteins of different subtypes from different sources, such as RSV A-type or RSV B-type RSV F proteins.

[0044] The second aspect of the present invention provides an immunogen comprising the RSV F protein according to the first aspect of the present invention.

[0045] In some embodiments, the immunogen comprises a multimer of the RSV F protein. In a preferred embodiment, the multimer is a trimer.

[0046] The third aspect of the present invention provides a virus-like particle comprising the RSV F protein described in the first aspect of the present invention or the immunogen described in the second aspect of the present invention.

[0047] The fourth aspect of the present invention provides a protein nanoparticle comprising the RSV F protein described in the first aspect of the present invention or the immunogen described in the second aspect of the present invention.

[0048] In some embodiments, the protein nanoparticles are ferritin nanoparticles, encapsulin nanoparticles, sulfur oxidoreductase (SOR) nanoparticles, 2,4-dioxotetrahydropterin synthase nanoparticles, or pyruvate dehydrogenase nanoparticles.

[0049] The fifth aspect of the present invention provides a nucleic acid molecule encoding the RSV F protein of the first aspect of the present invention, the immunogen of the second aspect of the present invention, the virus-like particle of the third aspect of the present invention, or the protein nanoparticle of the fourth aspect of the present invention.

[0050] In some embodiments, the nucleic acid molecule encodes a precursor protein of the immunogen, virus-like particle, or protein nanoparticle, wherein the precursor protein comprises a signal peptide, an F2 polypeptide, a Pep27 polypeptide, and an F1 polypeptide from the N-terminus to the C-terminus.

[0051] In some embodiments, the nucleic acid molecule is codon-optimized for expression in human or non-human mammalian cells.

[0052] Regardless of the source, the nucleic acid molecules encoding any of the aforementioned RSV F mutant proteins can be cloned into any suitable vector, such as a vector for nucleic acid molecule propagation or a vector for nucleic acid molecule expression. In embodiments where expression is desired, the nucleic acid can be operably linked to a promoter suitable for directed expression in a desired cell type, such as a mammalian cell or insect cell, and can be incorporated into any suitable expression vector, such as a mammalian or insect expression vector.

[0053] The sixth aspect of the present invention provides a vector comprising the nucleic acid molecule described in the fifth aspect of the present invention.

[0054] In some embodiments, the vector is a viral vector. The viral vector includes, but is not limited to, a bovine parainfluenza virus vector, a human parainfluenza virus vector, a Newcastle disease virus vector, a Sendai virus vector, a measles virus vector, an attenuated RSV vector, a paramyxovirus vector, an adenovirus vector, an alphavirus vector, a Venezuelan equine encephalitis vector, a Semliki Forest virus vector, a Sindbis virus vector, an adeno-associated virus vector, a poxvirus vector, a rhabdovirus vector, a vesicular stomatitis virus vector, a picornavirus vector, or a herpesvirus vector. In a preferred embodiment, the viral vector is selected from an adenovirus vector. The adenovirus is selected from a human adenovirus and a non-human adenovirus. The non-human adenovirus includes, but is not limited to, a simian, chimpanzee, gorilla, avian, canine, ovine, or bovine adenovirus. In a preferred embodiment, the adenovirus is selected from a chimpanzee adenovirus. In a more preferred embodiment, the chimpanzee adenovirus is an adenovirus in which at least the E1 gene is deleted.

[0055] The seventh aspect of the present invention provides a host cell comprising the nucleic acid molecule described in the fifth aspect of the present invention or the vector described in the sixth aspect of the present invention.

[0056] The eighth aspect of the present invention provides an immunogenic composition comprising the RSV F protein of the first aspect of the invention, the immunogen of the second aspect of the invention, the virus-like particle of the third aspect of the invention, the protein nanoparticle of the fourth aspect of the invention, the nucleic acid molecule of the fifth aspect of the invention, the vector of the sixth aspect of the invention, or the host cell of the seventh aspect of the invention; and a pharmaceutically acceptable carrier.

[0057] In some embodiments, the immunogenic composition further comprises an adjuvant. The adjuvant includes but is not limited to alum, oil-in-water composition, MF59, AS01, AS03, AS04, MPL, QS21, TLR9 agonist, TLR7 agonist, TLR4 agonist, TLR3 agonist, or a combination of two or more thereof.

[0058] The ninth aspect of the present invention provides a vaccine, which comprises the RSV F protein described in the first aspect of the present invention, the immunogen described in the second aspect of the present invention, the virus-like particles described in the third aspect of the present invention, the protein nanoparticles described in the fourth aspect of the present invention, the nucleic acid molecule described in the fifth aspect of the present invention, or the vector described in the sixth aspect of the present invention.

[0059] The tenth aspect of the present invention provides any of the following methods:

[0060] 1) A method for detecting or isolating RSV F binding antibodies in a subject, comprising: providing an effective amount of the RSV F protein of the first aspect of the invention, the immunogen of the second aspect of the invention, the virus-like particle of the third aspect of the invention, or the protein nanoparticle of the fourth aspect of the invention;

[0061] contacting a biological sample from the subject with the recombinant RSV F protein or the protein nanoparticle under conditions sufficient to form an immune complex between the recombinant RSV F protein or the protein nanoparticle and the RSV F-binding antibody; and

[0062] The immune complex is detected, thereby detecting or isolating the RSV F binding antibody in the subject.

[0063] In some embodiments, the subject is in the risk of RSV infection. In some embodiments, the subject has RSV infection. RSV infection comprises the RSV infection of various sources or hypotypes, including but not limited to human RSV hypotype A, human RSV hypotype B or cattle RSV infection.

[0064] 2) A method for stabilizing the prefusion conformation of an RSV fusion polypeptide, introducing the mutation described in the first aspect of the invention;

[0065] 3) A method for preparing RSV F antibodies, comprising immunizing a non-human animal with the RSV F protein of the first aspect of the invention or the immunogen of the second aspect of the invention to obtain antibodies;

[0066] In some embodiments, the non-human animal is a vertebrate, including but not limited to mice, rats, guinea pigs, rabbits, sheep, and non-human primates.

[0067] In some embodiments, the antibody comprises a chimeric, humanized antibody.

[0068] 4) A method for inducing an immune response against RSV in a subject in need thereof, characterized in that the method comprises administering to the subject a therapeutically effective amount of the RSV F protein of the first aspect of the invention, the immunogen of the second aspect of the invention, the virus-like particle of the third aspect of the invention, the protein nanoparticle of the fourth aspect of the invention, the nucleic acid molecule of the fifth aspect of the invention, the vector of the sixth aspect of the invention, the host cell of the seventh aspect of the invention, the immunogenic composition of the eighth aspect of the invention, or the vaccine of the ninth aspect of the invention.

[0069] The tenth aspect of the present invention provides any one of the following applications:

[0070] 1) Use of the RSV F protein of the first aspect of the invention, the immunogen of the second aspect of the invention, the virus-like particle of the third aspect of the invention, the protein nanoparticle of the fourth aspect of the invention, the nucleic acid molecule of the fifth aspect of the invention, the vector of the sixth aspect of the invention, the host cell of the seventh aspect of the invention, the immunogenic composition of the eighth aspect of the invention, or the vaccine of the ninth aspect of the invention in inhibiting or preventing RSV infection;

[0071] 2) Use of the RSV F protein of the first aspect of the invention, the immunogen of the second aspect of the invention, the virus-like particle of the third aspect of the invention, the protein nanoparticle of the fourth aspect of the invention, the nucleic acid molecule of the fifth aspect of the invention, the vector of the sixth aspect of the invention, the host cell of the seventh aspect of the invention, the immunogenic composition of the eighth aspect of the invention, or the vaccine of the ninth aspect of the invention in the preparation of a product for treating or preventing diseases associated with RSV infection;

[0072] 3) Use of the RSV F protein of the first aspect of the invention, the immunogen of the second aspect of the invention, the virus-like particle of the third aspect of the invention, the protein nanoparticle of the fourth aspect of the invention, the nucleic acid molecule of the fifth aspect of the invention, the vector of the sixth aspect of the invention, the host cell of the seventh aspect of the invention, the immunogenic composition of the eighth aspect of the invention, or the vaccine of the ninth aspect of the invention in the preparation of a product for inducing an immune response against RSV F protein in a subject;

[0073] 4) Use of the RSV F protein of the first aspect of the invention, the immunogen of the second aspect of the invention, the virus-like particle of the third aspect of the invention, the protein nanoparticle of the fourth aspect of the invention, the nucleic acid molecule of the fifth aspect of the invention, the vector of the sixth aspect of the invention, the host cell of the seventh aspect of the invention, the immunogenic composition of the eighth aspect of the invention, or the vaccine of the ninth aspect of the invention in the preparation of anti-RSV F protein antibodies;

[0074] 5) Use of the RSV F protein of the first aspect of the invention, the immunogen of the second aspect of the invention, the virus-like particle of the third aspect of the invention, the protein nanoparticle of the fourth aspect of the invention, the nucleic acid molecule of the fifth aspect of the invention, the vector of the sixth aspect of the invention, the host cell of the seventh aspect of the invention, or the immunogenic composition of the eighth aspect of the invention in the preparation of a vaccine;

[0075] 6) Use of the RSV F protein described in the first aspect of the invention, the immunogen described in the second aspect of the invention, the virus-like particle described in the third aspect of the invention, the protein nanoparticle described in the fourth aspect of the invention, the nucleic acid molecule described in the fifth aspect of the invention, the vector described in the sixth aspect of the invention, the host cell described in the seventh aspect of the invention, the immunogenic composition described in the eighth aspect of the invention, or the vaccine described in the ninth aspect of the invention in preparing a kit. BRIEF DESCRIPTION OF THE DRAWINGS

[0076] FIG1 is a flow cytometry result diagram of 293T cells infected with Ad-MF42 and Ad-wtF.

[0077] FIG2 is a graph showing the detection results of preF-specific antibodies in the serum of mice immunized with Ad-MF42 and Ad-wtF.

[0078] Figure 3 is a graph showing the results of neutralizing antibody titer detection.

[0079] FIG4 is a graph showing the ELISA test results for soluble RSV F protein.

[0080] Detailed Description of the Invention

[0081] The present invention has been extensively studied and, by mutating different amino acids, has discovered some new mutant RSV F proteins with improved properties. As shown in the Examples section of the present invention, these new mutant RSV F molecules have a higher expression level of the preF conformation and are highly immunogenic.

[0082] In the present invention, the use of alternatives (such as "or") should be understood to refer to any one, all or any combination of the alternatives. The terms "include", "have" and "include" are used synonymously in the present invention, and these terms and their variations are intended to be interpreted as non-limiting.

[0083] In the present invention, the term "RSV F protein" includes all forms of the protein, including F1 polypeptide and F2 polypeptide, i.e., including F0 precursor polypeptide, trimer of F0 precursor polypeptide, RSV F protomer and mature RSV F trimer - whether membrane-bound or soluble. As used in the present invention, the term "mutated RSV F protein" refers to an RSV F protein containing one or more artificially introduced / man-made mutations.

[0084] In the present invention, "F1 polypeptide" refers to a polypeptide comprising amino acid residues 137 to 513 of the RSV F F0 precursor sequence. Amino acid residues 137 to 513 do not include the RSV F transmembrane and cytoplasmic domains. In some embodiments, the F1 polypeptide may further include the RSV F transmembrane and cytoplasmic domains (located within residues 514 to 574 of the RSV F F0 precursor sequence).

[0085] "F2 polypeptide" refers to a polypeptide comprising amino acid residues 26 to 109 of the RSV F F0 precursor sequence.

[0086] In the present invention, the terms "protein" and "polypeptide" are used interchangeably.

[0087] In the present invention, the terms "nucleic acid molecule", "nucleic acid sequence", "nucleotide sequence" and "nucleic acid" are used interchangeably.

[0088] In the present invention, the term "adjuvant" refers to a substance that can enhance, accelerate or prolong the body's immune response to an immunogen or immunogenic composition (such as a vaccine).

[0089] RSV F protein

[0090] RSV is known to exist as a single serotype with two antigenic subtypes, A and B. The amino acid sequences of the two types of mature processed F proteins are approximately 93% identical. As used herein, amino acid positions are given with reference to the RSV F protein sequence from the A2 strain (AC083301.1, SEQ ID NO.1). Thus, the phrase "amino acid at position "x" of the RSV F protein" means the amino acid corresponding to the amino acid at position "x" in the RSV F protein of the RSVA2 strain of SEQ ID NO.1. Note that in the numbering system used in this application, 1 refers to the N-terminal amino acid of an immature F0 protein (SEQ ID NO.1). When a RSV strain other than the A2 strain is used, the amino acid positions of the F protein will be numbered with reference to the numbering of the F protein of the A2 strain of SEQ ID NO.1 by aligning the sequences of the other RSV strains with the F protein of SEQ ID NO.1 by inserting gaps where necessary. Sequence alignment is performed using methods well known in the art, for example, by CLUSTALW, Bioedit or CLC Workbench.

[0091] Sudden change among the present invention can be incorporated into any suitable RSV F sequence so that it is in preF conformation.Suitable RSV F sequence is the sequence of WT / natural RSV F molecule.Suitable RSV F sequence also comprises the sequence of sudden change RSV F molecule, promptly compared with WT / natural RSV F molecule, comprises the sequence of one or more artificially introduced sudden changes.

[0092] Those skilled in the art will appreciate that protein can be mutated by conventional molecular biology procedures. RSV F polypeptide is stable before the fusion in the compositions of the present invention, i.e., is difficult to become conformation after fusion when processing polypeptide (e.g., as purification, freeze-thaw cycles, and / or storage, etc.).

[0093] In certain embodiments, the RSV F protein is derived from the RSV A strain. In certain embodiments, the RSV F protein is derived from the RSV A2 strain of SEQ ID NO. 1.

[0094] In certain embodiments, the polypeptides according to the present invention further comprise a leader sequence, also known as a signal sequence or signal peptide, corresponding to amino acids 1-26 of SEQ ID NO. 1. This is a short (typically 5-30 amino acids long) peptide present at the N-terminus of most newly synthesized proteins destined for the secretory pathway. In certain embodiments, the polypeptides according to the present invention do not comprise a leader sequence.

[0095] In the present invention, embodiments of the specific exemplary amino acid sequences of the aforementioned mutations, or embodiments relating to specific regions of these sequences (e.g., F1 and / or F2 regions), variant forms equivalent to these amino acid sequences can also be used. In some embodiments, amino acid sequences having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity with the RSV F amino acid sequence of the present invention can be used across its F1 and F2 regions (especially across positions 26 to 109 (F2) and positions 137 to 513 (part of F1 that does not include transmembrane and cytoplasmic domains). Compared to one or more specific amino acid sequences provided by the invention, these variant forms may have added, deleted or substituted amino acids. Therefore, their length can be longer or shorter than the specific sequence.

[0096] In some embodiments, the transmembrane and cytoplasmic domains of these natural RSV F can be removed or changed to produce the RSV F molecule of soluble (i.e. non-membrane-bound) pattern, or can be replaced with different transmembrane and / or cytoplasmic domains. Similarly, in some embodiments, the transmembrane and cytoplasmic domains of these natural RSV F can be removed or changed to produce the RSV F molecule of soluble (i.e. non-membrane-bound) pattern, or can be replaced with different transmembrane and / or cytoplasmic domains. Similarly, in some embodiments, the transmembrane and cytoplasmic domains of these natural RSV F can be removed or changed to produce the RSV F molecule of soluble (i.e. non-membrane-bound) pattern, or can be replaced with different transmembrane and / or cytoplasmic domains. Similarly, in some embodiments, the transmembrane and cytoplasmic domains of these natural RSV F can be removed to produce the RSV F molecule of soluble (i.e. non-membrane-bound) pattern,

[0097] The mutant RSV F protein can be obtained and / or isolated and / or maintained in the preF conformation using any suitable method known in the art, including but not limited to standard protein purification methods, such as ion exchange chromatography, size exclusion chromatography, and / or affinity chromatography.

[0098] In some embodiments, mutant RSV F can be obtained, isolated, or maintained in the preF conformation by controlling the ionic strength of the medium / buffer in which the protein is present (e.g., by using a medium of high or low ionic strength). In some embodiments, mutant RSV F proteins can be obtained, isolated, or maintained at one or more temperatures that are conducive to preserving the preF conformation. In some embodiments, mutant RSV F proteins can be obtained, isolated, or maintained over a period of time that reduces the extent of loss of the preF conformation. The extent to which a protein formulation maintains one or more desired conformations (e.g., the preF conformation) can be determined by any suitable method known in the art, including but not limited to biochemical, biophysical, immunological, and virological analyses. These assays include, but are not limited to, for example, immunoprecipitation, enzyme-linked immunosorbent assay or enzyme-linked immunosorbent spot assay, crystallography (including co-crystallization with antibodies), sedimentation, analytical ultracentrifugation, dynamic light scattering (DLS), electron microscopy (EM), cryo-electron tomography, calorimetry, surface plasmon resonance (SPR), fluorescence resonance energy transfer (FRET), circular dichroism analysis, small angle x-ray scattering, neutralization assays, antibody-dependent cellular cytotoxicity assays, and / or in vivo challenge studies.

[0099] virus-like particles

[0100] In some embodiments, provide and comprise the virus-like particle (VLP) of the sudden change RSV F albumen as mentioned above that is stabilized in the pre-fusion conformation.VLP lacks the virus component required for viral replication and therefore presents the virus of highly attenuated form.When being administered to the experimenter, VLP can present the polypeptide that can induce the immune response for RSV (for example, being stabilized in the recombinant RSV F albumen of pre-fusion conformation).Virus-like particle and its manufacture method are known and well known to those of ordinary skill in the art, and the known formation VLP from the viral protein of some viruses, comprise human papilloma virus, HIV, human polyomavirus, rotavirus, parvovirus, canine parvovirus, hepatitis E virus and Newcastle disease virus.For example, contain the chimeric VLP of RSV antigen and can be the VLP based on Newcastle disease virus.VLP based on Newcastle disease has previously been shown to induce the neutralization immune response for RSV in mice.The formation of these VLPs can be detected by any suitable technology. Examples of techniques known in the art that are suitable for detecting VLPs in culture medium include, for example, electron microscopy, dynamic light scattering (DLS), selective chromatographic separation (e.g., ion exchange, hydrophobic interaction and / or size exclusion chromatography of VLPs), and density gradient centrifugation.

[0101] Protein nanoparticles

[0102] In some embodiments, a protein nanoparticle is provided that includes one or more of any of the disclosed mutant RSV F proteins stabilized in a prefusion conformation, wherein the protein nanoparticle is specifically bound by a prefusion-specific antibody (e.g., D25 or CR9501 antibody), and / or includes a RSV F prefusion-specific conformation (e.g., antigenic site Or V). Non-limiting examples of nanoparticles include ferritin nanoparticles, encapsulin nanoparticles, and sulfur oxidoreductase (SOR) nanoparticles, which are composed of assemblies of monomeric subunits comprising ferritin, encapsulin protein, and SOR protein, respectively. To construct protein nanoparticles comprising the disclosed recombinant RSV F protein stabilized in a prefusion conformation, an antigen is linked to a subunit of the protein nanoparticle (e.g., ferritin, encapsulin protein, or SOR protein). The fusion protein self-assembles into nanoparticles under appropriate conditions. The RSV F protein included on the protein nanoparticle can be human subtype A, human subtype B, or bovine RSV F protein, comprising the substitutions disclosed herein for prefusion stabilization.

[0103] Nucleic acid molecules

[0104] In some embodiments, the present invention provides nucleic acid molecules encoding mutant RSV F proteins of the present invention, and vectors comprising such nucleic acid molecules. In view of the generally known and understood nature of the genetic code among those of ordinary skill in the art, those of ordinary skill in the art can easily determine the nucleotide sequence of the nucleic acid molecules encoding any mutant RSV F proteins of the present invention.

[0105] Can use any suitable method known in the art, obtain or prepare the nucleic acid molecules of encoding sudden change RSV F molecule of the present invention.For example, the nucleic acid molecules of encoding sudden change RSV F molecule, can obtain from cloned DNA, or prepare by chemical synthesis.In some embodiments, nucleic acid molecules can be obtained by reverse transcription RNA, and wherein RNA is prepared by any method known to those of ordinary skill in the art.Point mutation, or any other modification of the present invention (for example, removing C-terminal sequence, replacing C-terminal sequence etc.), can be completed by the DNA standard recombination method that those of ordinary skill in the art are well aware of and understand.

[0106] In certain embodiments, the nucleic acid molecules encoding the protein according to the present invention are codon-optimized to be expressed in mammalian cells, preferably human cells. If, as compared with the wild-type sequence, at least one non-preferred codon is replaced by a more preferred codon, the sequence is considered to be codon-optimized. Here, a non-preferred codon is a codon that is not as frequently used as another codon encoding the same amino acid in a kind of organism, and a more preferred codon is a codon that is more frequently used than a non-preferred codon in a kind of organism. Preferably, more than one non-preferred codon, preferably the most or all non-preferred codons, are replaced by more preferred codons. Preferably, the codon most frequently used in a kind of organism is used for a codon-optimized sequence. Replacement by a preferred codon generally results in higher expression.

[0107] Those skilled in the art will appreciate that, due to the degeneracy of the genetic code, many different polynucleotides and nucleic acid molecules can encode the same polypeptide. It will also be understood that the skilled person can use conventional techniques to make nucleotide substitutions that do not affect the polypeptide sequence encoded by the nucleic acid molecule to reflect the codon usage of any specific host organism in which the polypeptide is to be expressed. Therefore, unless otherwise indicated, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Nucleotide sequences encoding proteins and RNA may or may not include introns.

[0108] viral vectors

[0109] In some embodiments, the present invention provides the method for the present invention to provide the recombinant RSV F of the present invention.Coding is stabilized in the nucleic acid molecule of the recombinant RSV F protein of the pre-fusion conformation and can be included in a viral vector, for example, to express antigen in host cell, or for the immunization of experimenter as disclosed in the present invention.In some embodiments, viral vector is administered to experimenter as a part for initial exemption-boosting vaccination.In some embodiments, viral vector is included in vaccine such as initial exemption vaccine or booster vaccine for initial exemption-boosting vaccination.

[0110] In some examples, a viral vector encoding a recombinant RSV F protein stabilized in a prefusion conformation can be replication-competent. For example, the viral vector can have a mutation in the viral genome (e.g., insertion of a nucleic acid encoding a PreF antigen) that does not inhibit viral replication in the host cell. The viral vector can also be conditionally replication-competent. In other examples, the viral vector is replication-defective in the host cell.

[0111] In some embodiments, the recombinant RSV F protein stabilized in the pre-fusion conformation is expressed by a viral vector that can be delivered via the respiratory tract. For example, paramyxovirus (PIV) vectors such as bovine parainfluenza virus (BPIV) vectors (for example, BPIV-1, BPIV-2 or BPV-3 vectors) or human PIV vectors, metapneumovirus (MPV) vectors, Sendai virus vectors or measles virus vectors are used to express disclosed antigens. The BPIV3 virus vector expressing RSV F and hPIV F protein (MEDI-534) is currently in clinical trials as an RSV vaccine. In another example, Newcastle disease virus vectors are used to express disclosed antigens. In another example, Sendai virus vectors are used to express disclosed antigens. Other viral vectors may also be used to express disclosed antigens, including polyomavirus, i.e., SV40, adenovirus, adeno-associated virus, vaccinia virus, herpes virus including HSV and EBV and CMV, Sindbis virus, alpha virus and retrovirus. Baculovirus (Autographa californica multiple nuclear polyhedrosis virus; AcMN PV) vectors are also known in the art and can be obtained from commercial sources. Other viral vectors are well known to those of ordinary skill in the art.

[0112] In some embodiments, the methods and compositions disclosed herein include adenoviral vectors expressing a recombinant RSV F protein stabilized in a prefusion conformation. Adenoviruses from various sources, subtypes, or subtype mixtures can be used as sources of viral genomes for adenoviral vectors. Non-human adenoviruses (e.g., monkey, chimpanzee, gorilla, avian, canine, ovine, or bovine adenoviruses) can be used to generate adenoviral vectors. For example, a simian adenovirus can be used as a source of viral genomes for adenoviral vectors. The simian adenovirus can have serotypes 1, 3, 7, 11, 16, 18, 19, 20, 27, 33, 38, 39, 48, 49, 50, or any other simian adenovirus serotype. Simian adenoviruses can be referred to using any suitable abbreviation known in the art, such as SV, SAdV, SAV, or sAV. In some examples, the simian adenovirus vector is a simian adenovirus vector having, but not limited to, serotypes 3, 7, 11, 16, 18, 19, 20, 27, 33, 38, or 39. In one example, a chimpanzee serotype Adc68 vector is used. Human adenovirus can be used as a source of viral genome for adenovirus vectors. Human adenovirus can be of various subgroups or serotypes. For example, the adenovirus can be of subgroup A (e.g., serotypes 12, 18, and 31), subgroup B (e.g., serotypes 3, 7, 11, 14, 16, 21, 34, 35, and 50), subgroup C (e.g., serotypes 1, 2, 5, and 6), subgroup D (e.g., serotypes 8, 9, 10, 13, 15, 17, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 36-39, and 42-48), subgroup E (e.g., serotype 4), subgroup F (e.g., serotypes 40 and 41), unclassified serogroups (e.g., serotypes 49 and 51), or any other adenovirus serotype. Replication-competent and replication-defective adenovirus vectors (including single and multiply replication-defective adenovirus vectors) are well known to those of ordinary skill in the art.

[0113] host cells

[0114] In the present invention, hosts can include microorganisms, yeast, insects, and mammalian organisms. Methods for expressing DNA sequences with eukaryotic or viral sequences in prokaryotes are well known in the art. Non-limiting examples of suitable host cells include bacteria, archaea, insects, fungi (e.g., yeast), plants, and animal cells (e.g., mammalian cells, such as humans). Exemplary cells used include Escherichia coli, Bacillus subtilis, Saccharomyces cerevisiae, Salmonella typhimurium, SF9 cells, C129 cells, 293 cells, Neurospora, and immortalized mammalian bone marrow and lymphocyte cell lines. Techniques for the proliferation of mammalian cells in culture are well known. Examples of commonly used mammalian host cell lines are VERO and HeLa cells, CHO cells, and WI38, BHK, and COS cell lines, but cell lines such as those designed to provide higher expression, desired glycosylation patterns, or other characteristics can be used. In some embodiments, the host cells include HEK293 cells or derivatives thereof, such as GnTI. - / - cell.

[0115] Host cells can be transformed with recombinant DNA by conventional techniques well known to those skilled in the art. When the host is prokaryotic (such as, but not limited to, E. coli), competent cells capable of DNA uptake can be prepared from cells collected after the exponential growth phase and subsequently treated by the CaCl2 method using procedures well known in the art. Alternatively, MgCl2 or RbCl can be used. Transformation can also be performed after forming protoplasts of the host cells or, if necessary, by electroporation.

[0116] When the host is a eukaryotic organism, these DNA transfection methods such as calcium phosphate coprecipitation, conventional mechanical procedures such as microinjection, electroporation, insertion of plasmids encapsulated in liposomes, or viral vectors can be used. Eukaryotic cells can also be co-transformed with a polynucleotide sequence encoding the disclosed antigens and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene. Another approach is to use a eukaryotic viral vector such as simian virus 40 (SV40) or bovine papilloma virus to transiently infect or transform eukaryotic cells and express the protein.

[0117] Composition

[0118] The RSV F albumen, virus-like particle, protein nanoparticle, nucleic acid molecule, host cell or multiple adjuvants of mutation disclosed by the present invention and optionally other treatment compositions such as antiviral drugs are combined together.In some embodiments, the composition comprising one or more disclosed RSV F albumen, virus-like particle, protein nanoparticle, nucleic acid molecule or host cell is an immunogenic composition.Described composition can include any RSV F albumen, it includes recombinant RSV F albumen as disclosed by the present invention (for example, including any protein nanoparticle of recombinant RSV F albumen as disclosed by the present invention), including any virus-like particle of recombinant RSV F albumen as disclosed by the present invention, encoding any nucleic acid molecule of recombinant RSV F albumen as disclosed by the present invention, or encoding or including any carrier of recombinant RSV F albumen as disclosed by the present invention.

[0119] These pharmaceutical compositions can be administered to a subject by various modes of administration known to those of ordinary skill in the art, for example, nasal, pulmonary, intramuscular, subcutaneous, intravenous, intraperitoneal, or parenteral routes.

[0120] To prepare the composition, the disclosed RSV F protein, virus-like particle, protein nanoparticle, viral vector or nucleic acid molecule can be combined with various pharmaceutically acceptable additives and a matrix or vehicle for dispersing the conjugate. Required additives include, but are not limited to, pH control agents such as arginine, sodium hydroxide, glycine, hydrochloric acid, citric acid, etc. In addition, local anesthetics (e.g., benzyl alcohol), isotonic agents (e.g., sodium chloride, mannitol, sorbitol), adsorption inhibitors (e.g., ), solubilizing agents (e.g., cyclodextrin and its derivatives), stabilizers (e.g., serum albumin) and reducing agents (e.g., glutathione). The composition may include adjuvants such as aluminum hydroxide, Freund's adjuvant, MPL TM , IL-12, TLR agonists (e.g., TLR-9 agonists), and many other suitable adjuvants well known in the art.

[0121] Disclosed RSV F albumen, virus-like particle, protein nanoparticle, viral vector or nucleic acid molecule can be dispersed in matrix or vehicle, and it can include the hydrophilic compound that can disperse antigen, and any required additive.Described matrix can be selected from the suitable compound of wide range, including but not limited to polycarboxylic acid or its salt, carboxylic anhydride (such as maleic anhydride) and other monomers (such as, (methyl) methyl acrylate, acrylic acid etc.) copolymer, hydrophilic vinyl polymer such as polyvinyl acetate, polyvinyl alcohol, polyvinyl pyrrolidone, cellulose derivative such as hydroxymethyl cellulose, hydroxypropyl cellulose etc., and natural polymer such as chitosan, collagen, sodium alginate, gelatin, hyaluronic acid and its nontoxic metal salt.Usually, select biodegradable polymer as matrix or vehicle, for example, polylactic acid, poly (lactic acid-glycolic acid) copolymer, polyhydroxybutyric acid, poly (hydroxybutyric acid-glycolic acid) copolymer and its mixture.Alternatively or additionally, synthetic fatty acid ester such as polyglycerol fatty acid ester, sucrose fatty acid ester etc. can be used as vehicle. Hydrophilic polymers and other vehicles can be used alone or in combination, and can impart enhanced structural integrity to the vehicle through partial crystallization, ionic bonding, cross-linking, etc. The vehicle can be provided in a variety of forms, including fluid or viscous solutions, gels, pastes, powders, microspheres, and films, for example, for direct application to mucosal surfaces.

[0122] Disclosed RSV F protein, virus-like particle, protein nanoparticle, viral vector or nucleic acid molecule can be combined with matrix or vehicle according to various methods, and the release of antigen can be formed by the disintegration of diffusion, vehicle or the related formation of water channel.In some cases, disclosed antigen or coding, expression or nucleic acid or viral vector comprising the antigen are dispersed in microcapsules (microspheres) or nanocapsules (nanospheres) prepared by suitable polymers (e.g., 2-isobutyl cyanoacrylate), and are dispersed in a biocompatible dispersion medium, which obtains continuous delivery and biological activity over the extended time.

[0123] The pharmaceutical composition may contain substances required to approximate physiological conditions as pharmaceutically acceptable vehicles, such as pH regulators and buffers, tonicity regulators, wetting agents, and the like, such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, and triethanolamine oleate. For solid compositions, conventional non-toxic pharmaceutically acceptable vehicles may be used, including, for example, pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like.

[0124] The pharmaceutical composition for using disclosed RSV F protein antigen, virus-like particle, protein nanoparticle, viral vector or nucleic acid molecule can also be mixed with solution, microemulsion or other ordered structures of the active component that is suitable for high concentration.Described vehicle can be the solvent or dispersion medium containing for example water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol etc.) and its suitable mixture.Can for example, by using coating such as lecithin, in the case of dispersible preparation, by maintaining required granularity, and by using surfactant to maintain the suitable fluidity of solution.In many cases, will wish to include isotonic agent in composition, for example sugar, polyol such as mannitol and sorbitol, or sodium chloride.Can produce the prolongation absorption of disclosed antigen by including the medicament that delays absorption in composition such as monostearate and gelatin.

[0125] In some embodiments, the disclosed RSV F protein, virus-like particle, protein nanoparticle, viral vector or nucleic acid molecule can be applied with a time-release preparation, for example, a composition comprising a slow-release polymer. These compositions can be prepared with a vehicle that will protect against rapid release, for example, a controlled-release vehicle such as a polymer, microencapsulated delivery system or a bioadhesive gel. The extended delivery in the various compositions of the present invention can be produced by including in the composition an agent (for example, aluminum monostearate hydrogel and gelatin) that delays absorption. When controlled-release preparations are needed, the controlled-release adhesive applicable according to the present invention includes any biocompatible controlled-release material that is inert to the activating agent and can be incorporated into disclosed antigens and / or other bioactivators. Numerous these materials are known in the art. Useful controlled-release adhesives are materials that are slowly metabolized under physiological conditions after it is delivered (for example, on mucosal surfaces, or in the presence of body fluids). Suitable adhesives include, but are not limited to, biocompatible polymers and copolymers well known in the art for sustained-release preparations. These biocompatible compounds are non-toxic and inert to surrounding tissues and do not trigger significant adverse side effects such as nasal irritation, immune response, inflammation, etc. They are metabolized into metabolites that are also biocompatible and easily removed from the body.

[0126] Exemplary polymeric materials for use include, but are not limited to, polymer matrices derived from copolymeric and homopolymeric polyesters having hydrolyzable ester bonds. Many of these are known in the art to be biodegradable and to produce degradation products that are non-toxic or have low toxicity. Exemplary polymers include polyglycolic acid and polylactic acid, poly(DL-lactic-co-glycolic acid), poly(D-lactic-co-glycolic acid), and poly(L-lactic-co-glycolic acid). Other useful biodegradable or bioerodible polymers include, but are not limited to, polymers such as poly(ε-caprolactone), poly(ε-caprolactone-co-lactic acid), poly(ε-caprolactone-co-glycolic acid), poly(β-hydroxybutyric acid), poly(2-alkyl cyanoacrylates), hydrogels such as poly(hydroxyethyl methacrylate), polyamides, poly(amino acids) (e.g., L-leucine, glutamic acid, L-aspartic acid, etc.), poly(ester ureas), poly(2-hydroxyethyl DL-asparagine), polyacetal polymers, polyorthoesters, polycarbonates, polymaleamides, polysaccharides, and copolymers thereof. Many methods for preparing these formulations are well known to those skilled in the art. Other useful formulations include controlled-release microcapsules, lactic acid-glycolic acid copolymers that can be used to make microcapsules and other formulations, and sustained-release compositions for water-soluble peptides.

[0127] Pharmaceutical composition is normally aseptic and stable under manufacturing, storage and use conditions.Can be by the disclosed RSV F albumen, virus-like particle, protein nanoparticle, viral vector or nucleic acid molecule of required amount being incorporated in the suitable solvent with one of listed composition of the present invention or combination, then filter sterilization prepares sterile solution when needed.Usually, by disclosed antigen and / or other bioactivator being incorporated in the sterile vehicle containing basic dispersion medium and from the other required components listed by the present invention those prepare dispersion liquid.In the case of sterile powder, preparation method comprises vacuum drying and lyophilization, and it obtains disclosed antigen and adds the powder of any additional required component from its previous sterile filtered solution.Can realize the prevention of microbial action by various antibacterial and antifungal agents for example parahydroxybenzoate, chlorobutanol, phenol, sorbic acid etc.The actual method that can be used for the preparation of composition will be known or obvious to those skilled in the art.

[0128] In some embodiments, the composition includes an adjuvant. Adjuvants are well known to those skilled in the art, for example, those that can be included in immunogenic compositions. In some embodiments, the adjuvant is selected to induce a Th1-biased immune response in a subject administered an immunogenic composition comprising an adjuvant and a disclosed antigen, or a nucleic acid or viral vector encoding, expressing, or including the antigen.

[0129] The amount of disclosed RSV F protein, viral vector or nucleic acid molecule can be changed according to, for example, specific antigen, route of administration and scheme and target population used. The amount utilized in the immunogenic composition is selected based on subject population (for example, infant or elderly). The optimal amount of a particular composition can be determined by standard studies involving antibody titers and other reactions observed in the subject. It should be understood that the antigen of the therapeutically effective amount in the immunogenic composition can include an amount that cannot induce an immune response by administering a single dose, but effectively (for example, in a primary immunization-boosting administration regimen) after administering multiple doses.

[0130] In several examples, pharmaceutical compositions for inducing an immune response against RSV in humans include disclosed RSV F proteins, viral vectors, or nucleic acid molecules for administration to a therapeutically effective amount of an infant (e.g., an initial dose age of birth to 1 year, e.g., an infant of 0 to 6 months) or an elderly patient subject (e.g., a subject greater than 65 years of age). It should be understood that the choice of adjuvant may differ in these different applications, and those skilled in the art can empirically determine the optimal adjuvant and concentration for each situation.

[0131] Treatment

[0132] In some embodiments, the disclosed RSV F protein, or nucleic acids, viral vectors, virus-like particles or protein nanoparticles, immunogenic compositions or vaccines encoding, expressing or comprising RSV F protein are used in a subject to induce an immune response against RSV. Thus, in some embodiments, a therapeutically effective amount of an immunogenic composition or vaccine comprising one or more of the disclosed RSV F protein, or nucleic acids or viral vectors encoding, expressing or comprising the antigen can be administered to a subject to generate an immune response against RSV.

[0133] In the present invention, a prophylactic or therapeutically effective amount of an immunogenic composition or vaccine comprising an RSV F protein, or a nucleic acid, viral vector, virus-like particle, or protein nanoparticle encoding, expressing, or comprising the antigen is administered to a subject in need of treatment for a duration and under conditions sufficient to prevent, inhibit, and / or ameliorate RSV infection in the subject. The immunogenic composition is administered in an amount sufficient to induce an immune response to an RSV antigen, such as the RSV F protein, in the subject.

[0134] In some embodiments, selection is for example owing to being exposed to RSV or being exposed to the possibility of RSV and having RSV infection or being in the experimenter under the risk of suffering from RSV infection for treatment.After applying the disclosed therapeutic composition of therapeutically effective amount, can be to experimenter monitoring RSV infection, the symptom relevant to RSV infection or both.Because almost all mankind can infect RSV before 3 years old, comprise whole birth population as immunization related colony.This can for example by any time from birth to 6 months old, from 6 months old to 5 years old, in pregnant woman (or women of childbearing age) with the passive transfer by antibody to protect its baby, newborn or fetus family member and age greater than 50 years old experimenter, start immunization scheme and carry out.

[0135] Immunogenic compositions can be used in collaborative vaccination schemes or combined formulations. In certain embodiments, the immunogenic compositions of combination and collaborative immunization schemes use independent immunogens or preparations, each for inducing an immune response to RSV antigens, such as an immune response to RSV F protein. The independent immunogenic compositions inducing an immune response to RSV antigens can be combined in a multivalent immunogenic composition that is administered to a subject in a single immunization step, or they can be administered independently (in a monovalent immunogenic composition) in a collaborative immunization scheme.

[0136] The administration of immunogenic compositions may be for prevention or treatment purposes. When provided prophylactically, before any symptom, for example, immunogenic compositions are provided before infection. The prophylactic administration of immunogenic compositions is used to prevent or improve any subsequent infection. When provided therapeutically, during or after the onset of symptoms of disease or infection, for example, after the symptom development of RSV infection, or after RSV infection diagnosis, immunogenic compositions are provided. Therefore, immunogenic compositions can be provided before expectation is exposed to RSV to weaken the expected severity, duration or degree of infection and / or related disease symptoms, or after exposure or suspected exposure to the virus, or after infection actual initiation, immunogenic compositions are provided.

[0137] For preventive and therapeutic purposes, immunogenic compositions can be delivered with a single bolus, over an extended period via continuous delivery (for example, continuous transdermal, mucosal or intravenous delivery), or administered to a subject with a repeated administration scheme (for example, by repeated administration schemes hourly, daily or weekly). The therapeutically effective dose of immunogenic compositions can be provided with repeated doses in the prevention or treatment scheme of extension, and the scheme will produce clinically significant results to alleviate one or more symptoms or detectable symptoms related to the target disease as described in the present invention or symptom. In the present invention, the determination of effective dose is typically based on animal model research, followed by human clinical trials, and is guided by the administration scheme of the generation or severity of the target disease symptoms or symptom significantly reduced in the subject. Suitable models in this regard include, for example, rodents, rats, pigs, cats, ferrets, non-human primates, and other generally recognized animal model subjects as known in the art. Alternatively, in vitro models (for example, immunology and histopathology assays) can be used to determine effective dose. Using these models, only routine calculations and adjustments are required to determine the appropriate concentration and dosage to administer a therapeutically effective amount of an immunogenic composition (e.g., an amount effective to elicit a desired immune response or alleviate one or more symptoms of a targeted disease). In alternative embodiments, an effective amount or dose of an immunogenic composition may simply inhibit or enhance one or more selected biological activities associated with a disease or condition as described herein for therapeutic or diagnostic purposes.

[0138] In one embodiment, suitable immunization scheme comprises and carries out at least three independent inoculations with one or more immunogenic compositions, wherein the second inoculation is to use after being inoculated for the first time greater than about two weeks, about three weeks to eight weeks or about four weeks.Usually, the third inoculation is to use after several months of the second inoculation, and in a specific embodiment, after being inoculated for the first time greater than about five months, after being inoculated for the first time greater than about six months to about two years, or after being inoculated for the first time about eight months to about one year.Also need to exceed the regular inoculation outside the third time to strengthen experimenter's " immune memory ".Can be by obtaining the aliquot sample of serum from experimenter and measuring antibody titer in the immunization program process and determine the suitability of selected vaccination parameter, for example, prescription, dosage, scheme etc.If this detection shows, vaccination is suboptimal, then experimenter can strengthen with the immunogenic composition of additional dose, and can expect the mode of enhancing immune response to regulate vaccination parameter.Expectation can have several strengthenings, and each strengthening can comprise identical or different RSV F albumen.

[0139] For the initial immunization-boosting scheme, the initial immunization can be administered in a single dose or multiple doses, for example, two doses, three doses, four doses, five doses or six doses or more can be administered to the subject within a few days, weeks or months. The boosting can be administered in a single dose or multiple doses, for example, two to six doses or more can be administered to the subject within a day, a week or months. Multiple boosting can also be given, for example, once to five times or more. Different dosages can be used in a series of continuous inoculations. For example, a relatively large dose is used in the primary inoculation, and then a relatively small dose is boosted. An immune response to the surface of a selected antigen can be generated by inoculating the subject once or multiple times with the immunogenic composition disclosed in the present invention.

[0140] Application of mutant RSV F

[0141] In some embodiments, the RSV F of the sudden change of the present invention can be used as a research tool, diagnostic tool, therapeutic agent, for the production of antibody reagents or as the target spot of therapeutic antibodies, and / or the component of vaccine or vaccine composition. For example, in some embodiments, the RSV F of the sudden change of the present invention can be used as the vaccine immunogen of animal subjects (such as mammalian subjects, including humans). It will be understood by those skilled in the art that the RSV F of the sudden change of the present invention can also be used for various other applications, and all these applications and purposes are intended to fall within the scope of the present invention.

[0142] Study of anti-RSV F antibodies

[0143] In one embodiment, the RSV F protein of the mutation of the present invention can be used as an analyte for testing and / or measuring the binding and / or titer of anti-RSV F antibodies, for example in an ELISA test, a Biacore / SPR binding assay, and / or any other antibody binding assay known in the art. For example, the RSV F protein of the mutation of the present invention can be used for analyzing and / or comparing the effects of anti-RSV F antibodies.

[0144] Producing antibodies

[0145] The mutant RSV F protein of the present invention or the material comprising the mutant RSV F protein can also be used to produce therapeutic antibodies, and / or can be used as the antibody of research tool, or for any other desired purposes. For example, the mutant RSV F protein of the present invention can be used for immunity, to obtain the RSV F protein antibody used as research tool and / or therapeutic agent. In some embodiments, in order to produce antibodies, the mutant RSV F protein of the present invention can be used for immune non-human animals, such as vertebrates, including but not limited to mice, rats, guinea pigs, rabbits, goats, non-human primates, etc. Such antibodies can then be obtained from animals, which can be monoclonal antibodies or polyclonal antibodies, and / or cells producing such antibodies. For example, in some embodiments, the mutant RSV F protein of the present invention can be used for immune mice, to produce and obtain monoclonal antibodies, and / or produce the hybridoma of this monoclonal antibody. These methods can be implemented using standard methods known in the art for producing mouse monoclonal antibodies, including standard methods for producing hybridomas. In some embodiments, the mutant RSV F protein of the present invention can be used to produce chimeric (such as partially human), humanized or fully human antibodies, for example, using any method currently known in the art for producing chimeric, humanized and fully human antibodies, including but not limited to CDR grafting methods, phage display methods, transgenic mouse methods (such as using mice genetically modified to be able to produce fully human antibodies, such as transgenic mice), and / or any other suitable method known in the art. One or a group of multiple antigens (preferably including the mutant RSV F protein of the present invention itself) can be used to characterize the antigenicity of antibodies prepared using this system for the mutant RSV F protein of the present invention. This antibody can be additionally characterized by any standard method known to those of ordinary skill in the art, including, but not limited to, ELISA-based methods, SPR-based methods, biochemical methods (such as, but not limited to, isoelectric point determination), and methods known in the art for studying the biodistribution, safety and effectiveness (such as in preclinical and clinical studies) of antibodies.

[0146] Subjects

[0147] In the present invention, the subject includes any animal species, particularly those susceptible to RSV infection or that can provide a model animal system for RSV infection research. In some embodiments, the subject is a mammalian species. In some embodiments, the subject is an avian species. Mammalian subjects include, but are not limited to, humans, non-human primates, rodents, rabbits, and ferrets. Avian subjects include, but are not limited to chickens, such as chickens from poultry farms. In a preferred embodiment, the subject is a human.

[0148] Reagent test kit

[0149] The present invention also provides a kit comprising a mutant RSV F protein of the present invention, or a composition comprising the mutant RSV F protein. To facilitate the use of the methods and compositions of the present invention, any component and / or composition described herein, as well as other components for experimental or therapeutic or vaccination purposes, can be packaged in the form of a kit. Typically, in addition to the above-mentioned components, the kit also includes other materials, which may include, for example, instructions for using the components, packaging materials, containers, and / or delivery devices.

[0150] Label or package insert will also typically include instructions for use in the method for treating or preventing RSV infection of RSV F protein or encoding, expression or nucleic acid or viral vector of the antigen. Package insert typically includes instructions for use in the commercial packaging of the therapeutic product as usual, which contains information about indications, usage, dosage, administration, contraindications and / or warnings about using this therapeutic product. Explanatory material can be written in electronic form (such as a computer floppy disk or CD) or can be visual (such as a video file). The test kit may also include other components to promote the specific application about the test kit design. The test kit may additionally include damping fluid and other reagents that are generally used for implementing ad hoc method. These test kits and suitable inclusions are well-known to those skilled in the art. DETAILED DESCRIPTION

[0151] The present invention will be further described in detail below with reference to the accompanying drawings and examples. The following examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0152] Example 1 Modification and screening of full-length transgenic F protein

[0153] 1.1F protein first round of modification

[0154] Using the reference sequence RSV A2 strain F protein (GeneBankAC083301.1, SEQ ID NO. 1) as a template, the following modifications were made: amino acid position 55 was mutated from S to V, and amino acid position 210 was mutated from Q to P; the extracellular region of the F protein contained a deletion of residues 104-144, and a glycine-serine dipeptide linker was added between residues 103 and 145 (i.e., sc9-10); amino acid position 215 was mutated from S to P (i.e., S215P), resulting in a mutant MF (sc9-10, S215P, SEQ ID NO. 2); and several point mutations were added to the extracellular region of MF (shown in Table 1). After constructing the corresponding plasmids, 293T cells were transfected. After labeling the cell surface F protein with an F protein antibody, the properties of the F protein mutants were analyzed by flow cytometry.

[0155] Table 1 Mutation sites

[0156] The codon-optimized F protein gene of RSV A2 strain was cloned into the pcDNA3.1 vector, namely pcDNA-wtF. A codon-optimized MF containing the above deletions and mutations was synthesized and cloned into the pcDNA3.1 vector, namely pcDNA-MF.

[0157] Plasmids containing the corresponding mutations listed in Table 1 were constructed. Primers overlapping the vector sequence were designed at the 5' and 3' ends of the MF ORF. Forward and reverse primers overlapping the site of the point mutation were designed. High-fidelity PCR with KOD enzyme was used to amplify the fragment upstream from the 5' end of the MF mutation site and the fragment downstream from the mutation site to the 3' end of the MF. Both fragments were cloned into linearized pcDNA-MF using homologous recombination, transformed into the site-directed mutagenesis plasmid, and successful recombination was confirmed by gene sequencing. Correctly sequenced clones were subjected to plasmid midi extraction and resequencing to verify plasmid sequence accuracy. DNA concentration was analyzed by spectrophotometer and stored frozen at -80°C.

[0158] The mutant plasmid was transfected into 293T cells. Multiple antibodies targeting different epitopes (Table 2) were used to bind to the F protein mutant expressed on the 293T cell surface. The antibodies used included D25 (McLellan JS et al., 2013), CR9501 (Gilman, MSA et al., 2019), Motavizumab (McLellan JS et al., 2010), and 4D7 (Espeseth, AS et al., 2020). The F protein antibody bound to the cell surface was then labeled with a secondary antibody, anti-human IgG Fc PE. Finally, the F protein on the cell surface was analyzed by flow cytometry. The specific steps are as follows:

[0159] On the first day, 293T cells were passaged into 6-well plates at 1.7 × 10 6 / well. On the second day, when the cell confluence reached 90%, cell transfection was performed. 88 μl OptiMEM, 2 μg plasmid, and 8 μl PEI were added to a 1.5 ml centrifuge tube in sequence. The mixture was gently shaken and placed at room temperature for 15 minutes before being suspended and added to 293T cells in one well of a 6-well plate. On the third day, the cell culture medium was discarded, the cells were washed with PBS, and then trypsin was added for digestion. After the cells shrank and dispersed, the trypsin was aspirated and the cells were suspended in PBS containing 2% serum; the cells were plated into a 96-well plate (2×10 5 / well); centrifuge at 350g for 3 min, remove the supernatant, add 100 μl of the primary antibody of the corresponding concentration in Table 2, and stain at 4°C in the dark for 30 min; centrifuge at 350g for 3 min, remove the supernatant, wash three times with washing solution, centrifuge at 350g for 3 min, remove the supernatant, add 100 μl of 200-fold diluted secondary antibody anti-human IgG Fc PE, and stain at 4°C in the dark for 30 min; centrifuge at 350g for 3 min, remove the supernatant, wash three times with washing solution, and finally resuspend the cells in washing solution and analyze by flow cytometry.

[0160] Table 2 Detection Antibodies

[0161] Using total fluorescence intensity as a reference value and normalized to the MwtF or MF values, the binding activity of the F mutants to each antibody was assessed. Antibody 4D7 staining was used to characterize the post conformation, antibodies D25 and CR9501 staining were used to characterize the pre conformation, and the antibody Motavizumab was used to reflect the expression level of the F mutant. The ratio results are shown in Tables 3 and 4 below. Table 3 shows the flow cytometry results of the mutants relative to wild-type MwtF, and Table 4 shows the flow cytometry results of the mutants relative to MF. The results in Table 3 show that S55V and Q210P significantly reduced the post conformational epitope while significantly increasing the pre conformation; N254R significantly reduced the post conformational epitope. The results in Table 4 showed that the mutations L188C-D263C, S190C-L260C, K394C-S491C, I475C-T323C, N254R, and S55V significantly reduced the post conformational epitope; N254R, K461P, S190C-L260C, and L188C-D263C significantly increased the pre conformation; and K461P, N254R, S190C-L260C, and I475C-T323C significantly increased the expression level.

[0162] Table 3 Flow cytometry results

[0163] Table 4 Flow cytometry results

[0164] 1.2F protein second round of modification

[0165] Based on the flow cytometry results from the first round of modification, we combined advantageous mutations to generate an F mutant with a more pre-like conformation. Therefore, we designed and added combined mutations based on the MF construct. After constructing the corresponding plasmids, we transfected 293T cells. After labeling the cell surface F protein with an F protein antibody, we analyzed the properties of the F protein mutants by flow cytometry.

[0166] Plasmids containing the corresponding mutations were constructed according to the method in 1.1. After plasmid midi extraction and sequencing verification, 293T cells were transfected and harvested one day later. Antibodies targeting different epitopes used in the first round of transformation were used to bind to the F protein mutants expressed on the 293T cell surface. The F protein antibodies bound to the cell surface were then labeled with a secondary antibody, anti-human IgG Fc (PE). Finally, flow cytometry was used to analyze the F protein expression on the cell surface. The binding activity of the F mutants with each antibody was assessed using total fluorescence intensity as a reference value and normalized to the MF value. The ratios are shown in Table 5. MF42 (MF + F190C / L260C, N254R, S55V), MF45 (MF + K461P, K394C / S491C), and MF46 (MF + K461P, I475C / T323C) significantly reduced the post conformation and somewhat increased the pre conformation of the F protein mutants.

[0167] Table 5 Flow cytometry results

[0168] 1.3 Adenovirus packaging

[0169] Adenovirus-based vaccines can deliver exogenous genes expressing antigens into the human body, offering numerous advantages, including high expression capacity, strong immunogenicity, stable production and storage, diverse immunization pathways, and the ability to stimulate a broad immune response with a single injection. The adenovirus vector used in this invention is AdC68, a rare chimpanzee adenovirus vector with very low pre-existing immunity in the human population. This vector has the E1 gene deleted and replaced with an expression cassette expressing the RSV F protein.

[0170] The genes for the transgenic F protein mutants MF42 and wtF were recombined into the E1 gene position of the AdC68 vector, respectively. After transfection into 293A cells, recombinant adenoviruses expressing the F protein, namely Ad-MF42 and Ad-wtF, were obtained. After obtaining the adenovirus seed, it was amplified and purified. The seed was added to 293A cells at 80%-90% confluence. After the cells showed typical pathological reactions, all cells and the supernatant were harvested. After repeated freeze-thaw cycles, the supernatant was collected by centrifugation, thus forming the adenovirus amplification medium. The adenovirus supernatant was precipitated using PEG8000, and the precipitate was collected after centrifugation. After reconstitution with PBS, the adenovirus was purified by cesium chloride density gradient centrifugation. The adenovirus-containing band was removed and dialyzed against a Tris buffer containing 5% sucrose.

[0171] After purification of the recombinant adenovirus, 293T cells were infected and the expression of F protein was analyzed. 293T cells were passaged into 6-well plates. When the confluence reached 80%-90%, 1×10 9 After VP purification of adenovirus, cells were harvested 48 hours later and antigen expression was analyzed by flow cytometry as described above.

[0172] The flow cytometry results are shown in Figure 1 . Ad-MF42 had obvious staining with pre-conformation antibodies (D25 and CR9501), while the staining level with post-conformation antibody (4D7) was low, indicating that Ad-MF42 expressed F protein with pre-conformation.

[0173] 1.4 Mouse immunization experiments

[0174] 1×10 10 VP recombinant adenoviruses Ad-wtF and Ad-MF42 were used to immunize SPF-grade BALB / c mice approximately 7 weeks old. A booster immunization was administered three weeks after the primary immunization. Immunization was by intramuscular injection. Three weeks after the second immunization, blood was collected, serum was isolated and inactivated, and the titers of preF-specific antibodies and neutralizing antibodies were measured.

[0175] The ELISA plate was coated with preF protein DS2 (M Gordon Joyce et al., 2016) overnight. The next day, serially diluted mouse serum was added. HPR-labeled anti-mouse IgG secondary antibody was then added. Finally, a chromogenic substrate was added for color development.

[0176] The ELISA results are shown in Figure 2. Compared with Ad-wtF, immunization with Ad-MF42 induced higher titers of preF-specific antibodies. Using the same method to immunize mice with other mutations, it was found that other mutations could induce higher titers of preF-specific antibodies compared to Ad-wtF.

[0177] Dilute the titrated RSV virus to 100TCID50 and add the diluted virus to a 96-well cell culture plate at 50μl per well. Then add the serially diluted serum to be tested at 50μl per well, with 4 wells per dilution, and incubate at 37°C for 2 hours. Trypsinize HEp-2 cells and passage them to a 96-well cell culture plate incubated with virus and serum at 100μl per well (approximately 3e+5 cells / well). Simultaneously, establish virus and cell controls. Observe the cytopathic effects under a microscope until the fifth day, and calculate the 50% effective concentration (IC50) of each serum.

[0178] The results of neutralizing antibody titer detection are shown in Figure 3. Compared with Ad-wtF, Ad-MF42 induced higher titers of RSV virus neutralizing antibodies.

[0179] Example 2: Modification of F protein

[0180] F190C / L260C, N254R, and S55V were used as the main mutations, and S215 and sc9-10 were replaced, respectively. After constructing plasmids containing the corresponding mutations, 293T cells were transfected and analyzed by flow cytometry. The total fluorescence intensity was used as the reference value and normalized to the WT value to evaluate the binding activity of the F mutants with various antibodies. The results are shown in Table 6.

[0181] Table 6 Flow cytometry results Note: The amino acids in quotation marks are the linker between F2 and F1. The first M corresponds to methionine at position 97 of the F protein, and the last A corresponds to alanine at position 149.

[0182] K461P and I475C / T323C were used as the main mutations, and S215 and sc9-10 were replaced, respectively. After constructing plasmids containing the corresponding mutations, 293T cells were transfected and analyzed by flow cytometry. The total fluorescence intensity was used as the reference value and normalized to the WT value to evaluate the binding activity of the F mutants with various antibodies. The results are shown in Table 7.

[0183] Table 7 Flow cytometry results Note: The amino acids in quotation marks are the linker between F2 and F1. The first M corresponds to methionine at position 97 of the F protein, and the last A corresponds to alanine at position 149.

[0184] Example 3 Detection of soluble F protein

[0185] The transmembrane region of the F protein was deleted, leaving only the extracellular region. Secreted F protein mutants and wtF containing a trimerization Foldon tag, as well as His and strep tags were expressed, and the F protein secreted into the culture supernatant was detected using a sandwich ELISA method.

[0186] The expressed soluble protein F mutations included: SF (sc9-10, S215P), SM42 (sc9-10, S215P, F190C / L260C, N254R, S55V), SM46 (sc9-10, S215P, K461P, I475C / T323C), SM59 (sc9-10, F190C / L260C, N254R, S55V, I214P), SM60 (sc9-10, F190C / L260C, N254R, S55V, S213P), SM61 (sc9-10, F190C / L260C, N254R, S55V, N216P), and SM65 (sc9-10, F215P, K461P, I475C / T323C). S M96 (sc9-10, F190C / L260C, N254R, S55V, S211P), SM97 (sc9-10, F190C / L26 0C, N254R, S55V, C212P), SM98 (sc9-10, F190C / L260C, N254R, S55V, I217P).

[0187] Primers were designed to amplify the N-terminus to amino acid 513 of the extracellular region of the model F protein. The C-terminus was fused with foldon, His, and Strep tags and then connected to the pcDNA3.1 vector. After sequencing and identification, the plasmid was extracted, the DNA concentration was measured by spectrophotometer, and then frozen in a -80℃ refrigerator.

[0188] The plasmid was transfected into 293F cells and the expressed F protein in the supernatant was collected for ELISA analysis. 6 / ml, aliquot into disposable filter membrane centrifuge tubes at 10ml / tube. To one 1.5ml centrifuge tube, add 500μl of blank culture medium and 10μg of plasmid, and mix thoroughly. To another 1.5ml centrifuge tube, add 450μl of blank culture medium and 40μl of PEI, and mix thoroughly. Combine the solutions in both centrifuge tubes, let stand at room temperature for 15 minutes, then add dropwise to the 293F cells and culture on a fixed shaker. After 4 days, collect the supernatant and centrifuge at 3000 rpm for 15 minutes.

[0189] Coat the ELISA plate with anti-Strep antibody overnight; add culture supernatant containing F mutants and wtF the next day to capture the F protein in the supernatant; add serially diluted F protein antibodies D25 and 4D7; add HPR-labeled anti-human IgG secondary antibody; and add color development substrate for color development.

[0190] The ELISA results are shown in Figure 4 , which showed that compared with wt and SF, all modified clones increased the pre conformation, while some clones decreased the post conformation.

[0191] The above embodiments are only provided for understanding the method and core concept of the present invention. It should be noted that, without departing from the principles of the present invention, a number of improvements and modifications may be made to the present invention by a person skilled in the art, and such improvements and modifications shall fall within the scope of protection of the claims of the present invention.

[0192] References:

[0193] McLellan JS, Chen M, Leung S, Graepel KW, Du 31;340(6136):1113-7.doi:10.1126 / science.1234914.Epub 2013Apr 25.PMID:23618766;PMCID:PMC4459498.

[0194] Gilman, MSA, Furmanova-Hollenstein, P., Pascual, G. et al. Transient opening of trimeric prefusion RSV F proteins. Nat Commun 10, 2105 (2019). https: / / doi.org / 10.1038 / s41467-019-09807-5.

[0195] McLellan JS,Chen M,Kim A,Yang Y,Graham BS,Kwong PD.Structural basis of respiratory syncytial virus neutralization by motavizumab.Nat Struct Mol Biol.2010Feb;17(2):248-50.doi:10.1038 / nsmb.1723.Epub 2010Jan 24.PMID:20098425;PMCID:PMC3050594.

[0196] Espeseth,A.S.,Cejas,P.J.,Citron,M.P.et al.Modified mRNA / lipid nanoparticle-based vaccinesexpressing respiratory syncytial virus F protein variants are immunogenic and protective in rodentmodels ofRSV infection.npj Vaccines 5,16(2020).https: / / doi.org / 10.1038 / s41541-020-0163-z.

[0197] Joyce,M.,Zhang,B.,Ou,L.et al.Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.Nat Struct Mol Biol 23,811–820(2016).

Claims

1. A mutant RSV F protein, characterized in that comprising at least one amino acid mutation that stabilizes the recombinant RSV F protein in a prefusion conformation, wherein the molecule is bound to the recognition antigen site and / or antibody binding to V; Preferably, the RSV F protein comprises a mutation at amino acid residue 55, 186-193, 210-217, 254, 255-264, 323, 394, 461, 475 or 491, or at an amino acid corresponding to residue 55, 186-193, 210-217, 254, 255-264, 323, 394, 461, 475 or 491 as determined by alignment with SEQ ID NO.

1.

2. RSV F protein according to claim 1, characterized in that The RSV F protein comprises a mutation at amino acid residue 55, 188, 190, 210-214, 217, 254, 260, 263, 323, 394, 461, 475 or 491; Preferably, the RSV F protein comprises an amino acid mutation that fills a cavity at position 55, or an amino acid mutation that introduces a disulfide bond at positions 188, 190, 260, 263, 394, 491, 323, 475, or an amino acid mutation that introduces a chemical bond at position 254, or an amino acid mutation that introduces an inducing polypeptide backbone rotation at positions 210-214, 217, 461; Preferably, the cavity-filling amino acid mutation comprises F, L, W, V, Y, H or M substitution; Preferably, the amino acid mutation for filling the cavity at position 55 is S55V; Preferably, the amino acid mutations that introduce disulfide bonds at positions 188, 190, 260, 263, 394, 491, 323, and 475 are replaced by cysteine; Preferably, the amino acid mutation that introduces a disulfide bond is selected from one or more of (a)-(d): (a) 188C and 263C substitutions; (b) 190C and 260C substitution; (c) 394C and 491C substitutions; and (d) 323C and 475C substitutions; Preferably, the 188C and 263C substitutions are L188C and D263C substitutions; The 190C and 260C substitutions are S190C and L260C substitutions; The 394C and 491C substitutions are K394C and S491C substitutions; The 323C and 475C substitutions are T323C and I475C substitutions; Preferably, the amino acid mutation that introduces a chemical bond at position 254 is N254R; Preferably, the amino acid mutation introduced to induce polypeptide backbone rotation comprises proline substitution; Preferably, the amino acid mutations introduced into positions 210-214, 217, and 461 to induce polypeptide backbone rotation are Q210P, C212P, S213P, I214P, I217P, or K461P; Preferably, the RSV F protein includes cavity-filling amino acid mutations, amino acid mutations that introduce chemical bonds, and at least one amino acid mutation that introduces a disulfide bond; Preferably, the RSV F protein comprises the following mutations: S55V, N254R, S190C and L260C; Preferably, the RSV F protein includes a mutation at position 461 and at least one amino acid mutation that introduces a disulfide bond; Preferably, the RSV F protein comprises the following mutations: K461P, K394C and S491C; or K461P, T323C and I475C; Preferably, the RSV F protein further comprises a mutation at position 215; Preferably, the mutation at position 215 is S215P; Preferably, the RSV F protein is an RSV A type or RSV B type RSV F protein; Preferably, the RSV F protein comprises an F1 polypeptide and an F2 polypeptide, and optionally does not comprise a pep27 polypeptide or a portion thereof; Preferably, the C-terminal residue of the F2 polypeptide and the N-terminal residue of the F1 polypeptide comprise RSV F positions 97 and 137, 97 and 145, 97 and 150, 102 and 144, 102 and 145, 102 and 146, 102 and 147, 103 and 144, 103 and 145, 103 and 146, 103 and 147, 104 and 144, 104 and 145, 104 and 146, 104 and 147, 105 and 144, 105 and 145, 105 and 146, 105 and 147, or 105 and 150, respectively; Preferably, the F2 and F1 polypeptides are linked via a heterologous peptide linker or directly linked; Preferably, the linker is selected from G, S, GG, GS, SG, PS, GP, GGG or GSG; Preferably, position 103 of the F2 polypeptide is linked to position 145 of the F1 polypeptide via a GS, PS linker; Preferably, position 103 of the F2 polypeptide is directly linked to position 145 of the F1 polypeptide; Preferably, position 103 of the F2 polypeptide is linked to position 147 of the F1 polypeptide via a GP linker; Preferably, the RSV F protein amino acid mutation S215P does not contain the pep27 polypeptide or a portion thereof; preferably, the F2 and F1 polypeptides of the RSV F protein are connected by a heterologous peptide linker; preferably, position 103 of the F2 polypeptide is connected to position 145 of the F1 polypeptide by a GS linker; Preferably, the RSV F protein comprises the following amino acid mutations: S55V, S190C, L260C and N254R, and one or more of Q210P, S211P, C212P, S213P, I214P, S215P or I217P; Preferably, the RSV F protein does not comprise a pep27 polypeptide or a portion thereof; Preferably, the F2 and F1 polypeptides of the RSV F protein are connected by a heterologous peptide linker; Preferably, the linker is selected from GS, PS, GP; Preferably, the RSV F protein comprises the following amino acid mutations: K461P, K394C, S491C and S215P, preferably, the RSV F protein does not comprise a pep27 polypeptide or a portion thereof; preferably, the F2 and F1 polypeptides of the RSV F protein are connected by a heterologous peptide linker; preferably, position 103 of the F2 polypeptide is connected to position 145 of the F1 polypeptide by a GS linker; Preferably, the RSV F protein comprises the following amino acid mutations: K461P, T323C, I475C and S215P; preferably, the RSV F protein does not comprise the pep27 polypeptide or a portion thereof; preferably, the F2 and F1 polypeptides of the RSV F protein are connected by a heterologous peptide linker; preferably, position 103 of the F2 polypeptide is connected to position 145 of the F1 polypeptide via a GS linker or position 103 of the F2 polypeptide is connected to position 147 of the F1 polypeptide via a GP linker; Preferably, the RSV F protein is a full-length RSV F protein; Preferably, the RSV F protein is a soluble RSV F protein; Preferably, the RSV F protein comprises one or more tags for detecting RSV F molecules; Preferably, the RSV F protein comprises one or more tags for purifying RSV F molecules; Preferably, the tag is selected from Strep tag, Strep II tag, FLAG tag, glutathione S-transferase (GST) tag, green fluorescent protein (GFP) tag, hemagglutinin A (HA) tag, histidine (His) tag, luciferase tag, maltose binding protein (MBP) tag, c-Myc tag, protein A tag or protein G tag; Preferably, the tag is a proteolytically cleavable tag.

3. An immunogen, characterized in that It comprises the RSV F protein of claim 1; Preferably, the immunogen comprises a multimer of the RSV F protein; Preferably, the multimer is a trimer.

4. A virus-like particle or protein nanoparticle, characterized in that: Comprising the RSV F protein of any one of claims 1-2 or the immunogen of claim 3. Preferably, the protein nanoparticles are ferritin nanoparticles, encapsulin nanoparticles, sulfur oxidoreductase (SOR) nanoparticles, 2,4-dioxotetrahydropterin synthase nanoparticles or pyruvate dehydrogenase nanoparticles.

5. A nucleic acid molecule, characterized in that Encoding the RSV F protein according to any one of claims 1 to 2, the immunogen according to claim 3, the virus-like particle or protein nanoparticle according to claim 4; Preferably, the nucleic acid molecule encodes a precursor protein of the immunogen, virus-like particle or protein nanoparticle; Preferably, the precursor protein comprises a signal peptide, an F2 polypeptide, a Pep27 polypeptide and an F1 polypeptide from the N-terminus to the C-terminus; Preferably, the nucleic acid molecule is codon optimized for expression in human or bovine cells; Preferably, the nucleic acid molecule is operably linked to a promoter.

6. A carrier, characterized in that Comprising the nucleic acid molecule of claim 5; Preferably, the vector is a viral vector; Preferably, the viral vector comprises a bovine parainfluenza virus vector, a human parainfluenza virus vector, a Newcastle disease virus vector, a Sendai virus vector, a measles virus vector, an attenuated RSV vector, a paramyxovirus vector, an adenovirus vector, an alphavirus vector, a Venezuelan equine encephalitis vector, a Semliki Forest virus vector, a Sindbis virus vector, an adeno-associated virus vector, a poxvirus vector, a rhabdovirus vector, a vesicular stomatitis virus vector, a picornavirus vector or a herpesvirus vector; Preferably, the viral vector is an adenoviral vector; Preferably, the adenovirus is selected from human adenovirus and non-human adenovirus; Preferably, the non-human adenovirus comprises a simian, chimpanzee, gorilla, avian, canine, ovine or bovine adenovirus; Preferably, the non-human adenovirus is selected from chimpanzee adenovirus; Preferably, the chimpanzee adenovirus is an adenovirus in which at least the E1 gene is deleted.

7. A host cell, characterized in that Comprising the nucleic acid molecule of claim 5 or the vector of claim 6.

8. An immunogenic composition, characterized in that Comprising the RSV F protein of any one of claims 1-2, the immunogen of claim 3, the virus-like particle or protein nanoparticle of claim 4, the nucleic acid molecule of claim 5, the vector of claim 6 or the host cell of claim 7; and a pharmaceutically acceptable carrier; Preferably, the immunogenic composition further comprises an adjuvant; Preferably, the adjuvant comprises alum, an oil-in-water composition, MF59, AS01, AS03, AS04, MPL, QS21, a TLR9 agonist, a TLR7 agonist, a TLR4 agonist, a TLR3 agonist or a combination of two or more thereof.

9. A vaccine, characterized in that The vaccine comprises the RSV F protein of any one of claims 1-2, the immunogen of claim 3, the virus-like particle or protein nanoparticle of claim 4, the nucleic acid molecule of claim 5 or the vector of claim 6.

10. Any of the following methods: 1) A method for detecting or isolating RSV F binding antibodies in a subject, comprising: Providing an effective amount of the RSV F protein according to any one of claims 1 to 2, the immunogen according to claim 3, and the virus-like particle or protein nanoparticle according to claim 4; contacting a biological sample from the subject with the recombinant RSV F protein or the protein nanoparticle under conditions sufficient to form an immune complex between the recombinant RSV F protein or the protein nanoparticle and the RSV F binding antibody; and detecting the immune complex, thereby detecting or isolating the RSV F binding antibody in the subject; Preferably, the subject is at risk for or has RSV infection; Preferably, the RSV infection is human RSV subtype A, human RSV subtype B or bovine RSV infection; Preferably, the subject is a human subject; 2) A method for stabilizing the pre-fusion conformation of an RSV fusion polypeptide, characterized by introducing a mutation as described in any one of claims 1 to 2; 3) A method for preparing RSV F antibodies, characterized in that the antibodies are obtained by immunizing non-human animals using the RSV F protein according to any one of claims 1 to 2 or the immunogen according to claim 3; Preferably, the non-human animal is a vertebrate; Preferably, the vertebrates include mice, rats, guinea pigs, rabbits, sheep, and non-human primates; Preferably, the antibodies include chimeric and humanized antibodies; 4) A method for inducing an immune response against RSV in a subject in need thereof, characterized in that the method comprises administering to the subject a therapeutically effective amount of the RSV F protein of claims 1-2, the immunogen of claim 3, the virus-like particle or protein nanoparticle of claim 4, the nucleic acid molecule of claim 5, the vector of claim 6, the host cell of claim 7, the immunogenic composition of claim 8 or the vaccine of claim 9.

11. Any of the following applications: 1) Use of the RSV F protein of claim 1-2, the immunogen of claim 3, the virus-like particle or protein nanoparticle of claim 4, the nucleic acid molecule of claim 5, the vector of claim 6, the host cell of claim 7, the immunogenic composition of claim 8 or the vaccine of claim 9 in inhibiting or preventing RSV infection; 2) Use of the RSV F protein of claims 1-2, the immunogen of claim 3, the virus-like particle or protein nanoparticle of claim 4, the nucleic acid molecule of claim 5, the vector of claim 6, the host cell of claim 7, the immunogenic composition of claim 8 or the vaccine of claim 9 in the preparation of a product for treating or preventing RSV infection-related diseases; 3) Use of the RSV F protein of claims 1-2, the immunogen of claim 3, the virus-like particle or protein nanoparticle of claim 4, the nucleic acid molecule of claim 5, the vector of claim 6, the host cell of claim 7, the immunogenic composition of claim 8 or the vaccine of claim 9 in the preparation of a product for inducing an immune response against RSV F protein in a subject; 4) Use of the RSV F protein of claims 1-2, the immunogen of claim 3, the virus-like particle or protein nanoparticle of claim 4, the nucleic acid molecule of claim 5, the vector of claim 6, the host cell of claim 7, the immunogenic composition of claim 8 or the vaccine of claim 9 in the preparation of anti-RSV F protein antibodies; 5) Use of the RSV F protein of claims 1-2, the immunogen of claim 3, the virus-like particle or protein nanoparticle of claim 4, the nucleic acid molecule of claim 5, the vector of claim 6, the host cell of claim 7 or the immunogenic composition of claim 8 in the preparation of a vaccine; 6) Use of the RSV F protein of claim 1-2, the immunogen of claim 3, the virus-like particle or protein nanoparticle of claim 4, the nucleic acid molecule of claim 5, the vector of claim 6, the host cell of claim 7, the immunogenic composition of claim 8 or the vaccine of claim 9 in the preparation of a kit.

Citation Information

Patent Citations

  • Prefusion RSV F proteins and their use

    CN105473604A

  • RSV f protein mutants

    CN108738312A

  • Antigen purification method

    CN112566654A

  • Mutant respiratory syncytial virus pre-fusion F protein and application thereof

    CN116284266A

  • Respiratory syncytial virus (RSV) polypeptide with immunogenicity

    CN117586359A